Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Kurtis D Davies1, P LouAnn Cable, Jennifer E Garrus
1Cell Biology, Array BioPharma, Inc., Boulder, Colorado, USA. kurtisdavies@hotmail.com
Abstract:
Inhibition of the checkpoint kinase Chk1, both as a monotherapy and in combination with DNA damaging cytotoxics, is a promising therapeutic approach for the treatment of a wide array of human cancers. However, much remains to be elucidated in regard to the patient populations that will respond best to a Chk1 inhibitor and the optimal therapeutics to combine with a Chk1 inhibitor. In an effort to discover sensitizing mutations and novel combination strategies for Chk1 inhibition, an siRNA screen was performed in combination with the selective Chk1 inhibitor AR458323. This screen employed a custom made library of siRNAs targeting 195 genes, most of which are involved in cell-cycle control or DNA damage repair. One of the most prominent and consistent hits across runs of the screen performed in three different cancer cell lines was Wee1 kinase. MK-1775 is a small molecule inhibitor of Wee1 that is currently in early stage clinical trials. In confirmation of the results obtained from the siRNA screen, AR458323 and MK-1775 synergistically inhibited proliferation in multiple cancer cell types. This antiproliferative effect correlated with a synergistic induction of apoptosis. In cellular mechanistic studies, the combination of the two molecules resulted in dramatic decreases in inhibitory phosphorylation of cyclin-dependent kinases, an increase in DNA damage, alterations in cell-cycle profile, and collapse of DNA synthesis. In conclusion, the clinical combination of a Chk1 inhibitor and a Wee1 inhibitor holds promise as an effective treatment strategy for cancer.
Insights
Combining Chk1 inhibitors with Wee1 inhibitors shows promise for cancer treatment. This combination synergistically inhibits cancer cell proliferation and induces apoptosis, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Checkpoint kinase 1 (Chk1) inhibition is a potential cancer therapy, but optimal combinations and responsive patient groups require further study.
- Identifying novel combination strategies and sensitizing mutations for Chk1 inhibitors is crucial for advancing cancer treatment.
- Wee1 kinase is a key regulator of cell cycle progression and a potential target in cancer therapy.
Purpose of the Study:
- To discover sensitizing mutations and novel combination strategies for Chk1 inhibition.
- To evaluate the combination of a Chk1 inhibitor (AR458323) with a Wee1 inhibitor (MK-1775) for cancer treatment.
- To elucidate the cellular mechanisms underlying the synergistic effects of combined Chk1 and Wee1 inhibition.
Main Methods:
- Conducted an siRNA screen targeting 195 genes involved in cell-cycle control and DNA damage repair, combined with the Chk1 inhibitor AR458323.
- Utilized three different cancer cell lines to identify consistent hits from the siRNA screen.
- Confirmed synergistic effects of AR458323 and MK-1775 on cancer cell proliferation and apoptosis through in vitro studies.
Main Results:
- Wee1 kinase was identified as a prominent hit in the siRNA screen, suggesting its role in sensitizing cells to Chk1 inhibition.
- The combination of AR458323 (Chk1 inhibitor) and MK-1775 (Wee1 inhibitor) demonstrated synergistic inhibition of cancer cell proliferation across multiple cell types.
- Combined inhibition led to synergistic apoptosis induction, decreased inhibitory phosphorylation of cyclin-dependent kinases, increased DNA damage, cell-cycle alterations, and collapsed DNA synthesis.
Conclusions:
- The combination of Chk1 and Wee1 inhibitors represents a promising therapeutic strategy for various human cancers.
- This combination induces significant anti-proliferative effects and apoptosis through mechanisms involving DNA damage and cell-cycle disruption.
- Further clinical investigation of combined Chk1 and Wee1 inhibition is warranted for cancer treatment development.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
01:23Negative Regulator Molecules
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
01:27Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...